Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.

Deans ZC, Tull J, Beighton G, Abbs S, Robinson DO, Butler R.

Genet Test Mol Biomarkers. 2011 Nov;15(11):777-83. doi: 10.1089/gtmb.2010.0239. Epub 2011 Aug 18.

PMID:
21851273
2.

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.

Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J.

Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620. Review.

3.

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.

Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN.

Arch Pathol Lab Med. 2009 Oct;133(10):1600-6. doi: 10.1043/1543-2165-133.10.1600. Review.

PMID:
19792050
4.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q, Hou F.

Colorectal Dis. 2014 Nov;16(11):O370-8. doi: 10.1111/codi.12749. Review.

PMID:
25155261
5.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
6.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
7.

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A.

Cancer Treat Rev. 2009 May;35(3):262-71. doi: 10.1016/j.ctrv.2008.11.005. Epub 2008 Dec 30. Review.

PMID:
19117687
8.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
9.

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.

Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29. Review.

PMID:
22039088
10.

KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL.

Cancer. 2013 Feb 15;119(4):714-21. doi: 10.1002/cncr.27804. Epub 2012 Sep 12. Review.

11.

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.

Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12. Review.

PMID:
25115304
12.

Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.

Hoorens A, Jouret-Mourin A, Sempoux C, Demetter P, De Hertogh G, Teugels E.

Acta Gastroenterol Belg. 2010 Oct-Dec;73(4):497-503. Review.

PMID:
21299161
13.

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.

Ruzzo A, Graziano F, Canestrari E, Magnani M.

Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. Review.

PMID:
20088793
14.

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.

Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, Li J, Chen Q.

Eur J Cancer. 2010 Oct;46(15):2781-7. doi: 10.1016/j.ejca.2010.05.022. Epub 2010 Jun 25. Review.

PMID:
20580219
15.

KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.

Wang HL, Lopategui J, Amin MB, Patterson SD.

Adv Anat Pathol. 2010 Jan;17(1):23-32. doi: 10.1097/PAP.0b013e3181c6962f. Review.

PMID:
20032635
16.

To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.

Kim R, Kubal T.

Clin Colorectal Cancer. 2012 Jun;11(2):85-7. doi: 10.1016/j.clcc.2011.10.005. Epub 2011 Dec 9. Review. No abstract available.

PMID:
22169039
17.

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. Review.

PMID:
21129611
18.

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.

Mancl EE, Kolesar JM, Vermeulen LC.

Am J Health Syst Pharm. 2009 Dec 1;66(23):2105-12. doi: 10.2146/ajhp090036. Review.

PMID:
19923311
19.

Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.

Chen J, Ye Y, Sun H, Shi G.

Cancer Chemother Pharmacol. 2013 Jan;71(1):265-72. doi: 10.1007/s00280-012-2005-9. Epub 2012 Oct 23. Review.

PMID:
23090619
20.

[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].

Dubská L, Vyskocilová M, Nenutil R, Valík D, Knoflícková D, Fabian P, Kocáková I, Demlová R, Beránek M, Drastíková M, Vosmiková H, Bóday A, Horká K, Símová J, Drábek J, Ehrmann J, Hajdúch M, Matejcková M, Síma R, Tvrdík D, Povýsil C, Ryska A.

Cas Lek Cesk. 2011;150(6):321-6. Review. Czech.

PMID:
21751504

Supplemental Content

Support Center